ライフサイエンスコーパス: RAR

1 RAR alpha can interact with ER-binding sites, but this o

2 RAR signaling upregulates two important genes, Tbx1 and

3 RAR-related orphan receptor gamma (RORgamma) is a nuclea

4 RAR-related orphan receptor-gammat (ROR-gammat) directs

5 RAR/RXR and AhR pathways cross-talk at the levels of lig

6 RARs control multiple genes, whereas RXRs serve as partn

7 RARs regulate transcription, but their function in the c

8 posite fetal risk was lowest with LMWH (13%; RAR: 0.3; 95% CI: 0.1 to 0.8), compared with VKA (39%),

9 terval [CI]: 1.5 to 7.5), LMWH and VKA (16%; RAR: 3.1; 95% CI: 1.2 to 7.5), or UFH and VKA (16%; RAR:

10 1; 95% CI: 1.2 to 7.5), or UFH and VKA (16%; RAR: 3.1; 95% CI: 1.5 to 7.1).

11 sly unidentified IL-23 receptor (IL-23R)(+), RAR-related orphan receptor gammat (ROR-gammat)(+)CD3(+)

12 Our findings implicate a RAR-beta/MLC-2 pathway in peritumoural stromal remodelli

13 te cell cycle and cancer cell apoptosis in a RAR-independent fashion, thereby avoiding atRA's toxicit

14 ultaneous mutation of these motifs abolishes RAR binding and concomitantly leads to loss of repressio

15 previously demonstrated that retinoic acid (RAR-RXR) and vitamin D3 receptors (VDR-RXR) heterodimers

16 hat the diminished ability of RA to activate RAR following induction of differentiation stems from do

17 beta-apocarotenoids significantly activated RARs.

18 peptide in vitro, its potency in activating RAR-controlled genes in cell-based assays was much lower

19 -repressor (c-SMRT), a constitutively active RAR (VP16-RARgamma2), or by treatment with an RARgamma-s

20 novel paracrine loop controlled by adipocyte-RAR that regulates the mammary ductal tree morphogenesis

21 helium showed that when activated, adipocyte-RARs contribute to generation of secreted proliferative

22 large number of genes regulated by adipocyte-RARs.

23 The high-affinity Ajuba-RAR/RXR interaction site overlaps the region responsible

24 ine methyltransferase-5) inhibited the Ajuba/RAR interaction.

25 s fused to the retinoic acid receptor alpha (RAR).

26 Retinoic acid receptor-alpha (RAR alpha) is a known estrogen target gene in breast can

27 tinoic acid receptor-related receptor alpha, RAR may act as a novel component to induce hepatic FGF21

28 In addition, an RAR-gamma agonist blocked heterotopic ossification in tr

29 Znf703 is an RAR- and Wnt-inducible transcription factor that exhibit

30 Of note, an RAR pan-antagonist, LE540, also inhibited I (Ca) but pro

31 treated mouse mesenchymal stem cells with an RAR-gamma agonist and transplanted them into nude mice.

32 Publicly available AR and RAR ChIP-seq data was used to find gene potentially regu

33 to find gene potentially regulated by AR and RAR.

34 ice induced expression of PPARbeta/delta and RAR target genes involved in regulation of lipid homeost

35 e show that AM580, a retinoid derivative and RAR-alpha agonist, is highly potent in interrupting the

36 nts that enhance RAR repressor function; and RAR/Zac1 function on aggrecan expression may involve Sox

37 s, a portion of T-cell clones both GATA3 and RAR-related orphan receptor C (RORC) or RORC alone, conf

38 ubmandibular gland express T-bet, GATA3, and RAR-related orphan receptor gamma, thymus-specific isofo

39 17 cell differentiation, including Il6ra and RAR-related orphan receptor gamma (Rorc), but not of Il4

40 Using structural and biophysical methods and RAR as a model, we could dissect the molecular mechanism

41 romyelocytic leukemia zinc finger (PLZF) and RAR-related orphan receptor gamma (RORgammat).

42 unds as the ligands of Crabp1 to rapidly and RAR-independently activate extracellular signal regulate

43 f tumor suppressor genes such as RASSF1A and RAR-beta, which are frequently silenced in human lung ca

44 e activation by recruiting co-regulators and RAR:RXR or beta-catenin, suggesting an unexpected collab

45 vivo within their heterodimers, the RXR and RAR isotypes are not functionally redundant, and it also

46 This review discusses RA and RARs and their complex roles in innate and adaptive immu

47 tinoid and retinoic acid receptors (RXRs and RARs), leading to physiological and pharmacologic effect

48 oth proximal and distal promoter regions are RAR responsive with the latter having RA response elemen

49 ism involving a retinoic acid receptor beta (RAR-beta)-dependent downregulation of actomyosin (MLC-2)

50 a conserved RARE upstream of Fgf8 that binds RAR isoforms in mouse embryos.

51 Both RAR and RXR signaling events are implicated in hippocamp

52 CRABP2 and for transcriptional activation by RAR.

53 the transcriptional up-regulation of Mct8 by RAR is likely to be important for extraembryonic endoder

54 ting that conversion can also be mediated by RAR alpha 2.

55 RA effects are mediated by RAR/RXR receptors that we show are modified by interacti

56 The degree of control by RARs or other transcription factors would in turn depend

57 lts indicate that atRA signaling mediated by RARs is required in the adult pancreas for maintaining b

58 To define the genetic network regulated by RARs in breast cancer, we identified RAR genomic targets

59 miR-18a deficiency enhanced CCR6(+) RAR-related orphan receptor (ROR)gammat(+) Th17 cell dif

60 uggested that reagents blunting donor T-cell RAR signaling may possess therapeutic anti-GVHD properti

61 yoid bodies or F9 embryonal carcinoma cells, RARs occupy a large repertoire of sites with DR0, DR8, a

62 rowth factor stimulation while circumventing RAR-mediated retinoid toxicity.

63 osynthesis, and requires Med25 to coordinate RAR, STAT6 and chromatin remodeler, Brg1 to remodel the

64 d proteins GATA3 and IL-4 without decreasing RAR-related orphan receptor gamma (RORgammat), IL-17, an

65 CD4(+) T cells is not a result of defective RAR-related orphan receptor gammat (RORgammat) expressio

66 rget sites, independently of the downstream, RAR-mediated steps of transcription.

67 genetically encoded reporter shows elevated RAR signaling in degenerated retinas from murine RP mode

68 or Zac1 or pharmacologic agents that enhance RAR repressor function; and RAR/Zac1 function on aggreca

69 Our data imply that RAR agonist enhances RAR-RXR heterodimerization, and chromatin binding/dimeri

70 Enhancing RAR signaling in healthy retinas mimics the pathophysiol

71 on-specific enhancer that contains essential RAR, T-bet, and Sox3 motifs.

72 ding of the Th17 master transcription factor RAR-related orphan receptor gamma t variant (RORgammat)

73 for E-cadherin, 25.9% for p16, and 27.5% for RAR-beta(2).

74 Our studies establish that hypomorphism for RAR in beta-cells leads to an age-dependent decrease in

75 Our results show that UTX is important for RAR-mediated transcription and provide insight into the

76 Thus, it seems that the binary model for RAR function does not apply to all in vivo scenarios.

77 dependent manner, providing a novel role for RAR alpha that is independent of its classic role.

78 These results establish a novel role for RAR as a regulator of spatial patterning of the PPE thro

79 DCA7L, CDK6, BTG1 and SAMD3) were tested for RAR and AR binding and two of them (CDCA7L and CDK6) pro

80 teract with their DNA response elements (for RARs: retinoic acid response elements or RAREs) in the r

81 le genes, whereas RXRs serve as partners for RARs and other nuclear receptors that regulate metabolis

82 dence that the retinoic acid receptor gamma (RAR-G) plays a major role in the regulation of the hTGP

83 ving a nuclear retinoic acid receptor-gamma (RAR-gamma) agonist.

84 /RXR-alpha and retinoic acid receptor-gamma (RAR-gamma)/RXR-beta are bound as repressing complexes to

85 ata-3(+/nlslacZ) (Gata-3-haploinsufficient), RAR-related orphan receptor alpha (RORalpha)(fl/fl)IL7R(

86 The hepatic RAR-FGF21 pathway may represent a potential drug target

87 However, whether hepatic RAR is linked to FGF21 in the control of lipid metabolis

88 IFN regulatory factor 4 and nuclear hormone RAR-related orphan receptor gammat protein levels in T c

89 Less is understood about how RAR regulates somite patterning, rostral-caudal boundary

90 ated by RARs in breast cancer, we identified RAR genomic targets using chromatin immunoprecipitation

91 During a microarray screen to identify RAR targets, we identified a subset of genes that patter

92 onal progenitors is mediated by the CRABP-II/RAR path and that the FABP5/PPARbeta/delta path can inhi

93 These findings implicate RAR alpha as an essential component of the ER complex, p

94 for growth plate function, its deficiency in RAR-mutant mice is likely to have contributed directly t

95 eated conditional mouse mutants deficient in RAR expression in cartilage.

96 of VE-cadherin was substantially reduced in RAR mutants, and this deficiency may underlie the arch a

97 elongation and are upregulated by increased RAR-mediated repression.

98 Increasing RAR signaling accelerated GVHD lethality, whereas donor

99 receptor subtype, as ATRA remarkably induced RAR-beta mRNA levels, whereas RAR-beta knockdown substan

100 In analyzing how ATRA induces RAR-dependent transcriptional upregulation of TRAIL-R1,

101 anistic studies showed that CBFA2T3 inhibits RAR target gene transcription by acting at an early step

102 ic groups, where those with a relatively low RAR usually correspond to incorrect annotations.

103 id receptor gamma 2 (RARgamma2) is the major RAR isoform expressed throughout the caudal axial progen

104 Mean RAR differences among countries ranged from 9.4 (Singapo

105 s that atRA treatment or adenovirus-mediated RAR-alpha overexpression significantly reduced hepatic f

106 determine the role of CYP26A1 in modulating RAR activation via formation and elimination of active r

107 tivator promotes formation of nonsymmetrical RAR homodimers with a 21 stoichiometry.

108 Consistent with this observation, RAR binding to DR-11, but not to Pal-17, was detected by

109 The differential ability of RAR-RXR bound to DR0 compared to DR2, DR5, and DR8 to me

110 by concomitantly promoting the activation of RAR and inhibiting the activation of PPARbeta/delta, SLC

111 s occurred through synergistic activation of RAR and RXR nuclear receptors.

112 thus impairs CRABP-II-mediated activation of RAR.

113 Antagonism of RAR signaling and deficiency in RARalpha (Rara(-/-)) res

114 oprecipitation assay demonstrated binding of RAR and retinoid X receptor to the RA response element.

115 The consequence of RAR alpha induction by estrogen was previously unknown.

116 monstrate that Ripply3, acting downstream of RAR signaling, is a key player in establishing boundarie

117 Here we investigate the effect of RAR-beta signaling on mitochondrial trafficking during n

118 eadily found at the RARE control elements of RAR endogenous target genes.

119 ose a parsimonious model of the evolution of RAR function during chordate anterior-posterior patterni

120 Identification of RAR as the trigger for hyperactivity presents a degenera

121 is promoted by the estrogen-ER induction of RAR alpha.

122 Finally, pharmacologic inhibition of RAR activation during the differentiation of the murine

123 Gene therapy inhibition of RAR increases innate and learned light-elicited behavior

124 Drug inhibition of RAR reduces hyperactivity in degenerating retinas and un

125 The inhibition of RAR signaling augmented donor-induced Treg generation an

126 CRABP-II thus facilitates the ligation of RAR and markedly enhances its transcriptional activity.

127 This prevailing model of RAR mechanism has been derived mostly from in vitro stud

128 The problems of RAR are most acute in the very setting for which RAR has

129 the first comparative studies of the role of RAR isoforms in CD8(+) T cell immunity.

130 ously unrecognized but frequent signature of RAR binding elements.

131 I-beta-mediated transcriptional silencing of RAR-beta Notably, EAD was the most effective combination

132 formational change bringing the N-termini of RAR and RXR closer together.

133 Use of RAR is discouraged.

134 lta and is further enhanced by activation of RARs.

135 n immunoprecipitation assays, the binding of RARs to the proximal RARE1 and distal RARE2, -3, and -4

136 etinoic acid in promoting the interaction of RARs with a coactivator peptide in vitro, its potency in

137 fied that regulate the multifaceted roles of RARs in the salamander limb including regulation of skel

138 antagonized ATRA-induced transactivation of RARs.

139 alidated the inhibitory effect of CBFA2T3 on RAR in multiple AML subtypes and patient samples.

140 constitutive activity of neuronal RXR and/or RAR alters calcium influx via the VGCCs.

141 at are deficient in RA-generating enzymes or RARs have been instrumental in identifying RA functions,

142 d stimulated Nrip1 expression, whereas a pan-RAR antagonist strongly reduced it.

143 The pan-RAR agonist 4-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetrame

144 being the RARgamma agonist CD437 and the pan-RAR agonist TTNPB.

145 PML-RAR, however, is not sufficient to induce disease in mic

146 c leukemia-retinoic acid receptor alpha (PML-RAR-alpha) oncoprotein.

147 rmalities such as oncogenes BCR-ABL1 and PML-RAR, mutations in BRCA1 and/or BRCA2 genes, and gene exp

148 ncofusion proteins, such as AML1-ETO and PML-RAR-alpha, involves the targeting of histone deacetylase

149 f APL, Hdac1 counteracts the activity of PML-RAR in (1) blocking differentiation; (2) impairing genom

150 ed to an expansion of a subpopulation of PML-RAR-expressing cells that is the major source of leukemi

151 (HDACs) by the oncogenic fusion protein PML-RAR is involved in the pathogenesis of acute promyelocyt

152 locytic leukemia-retinoic acid receptor (PML-RAR)alpha (PR), the fusion protein that initiates acute

153 -mediated proteasomal degradation of the PML-RAR fusion protein.

154 rthermore, the induced expression of the PML-RAR-alpha oncoprotein increased the expression of cell s

155 ease by promoting the destruction of the PML-RAR-alpha oncoprotein.

156 activity observed after induction of the PML-RAR-alpha oncoprotein.

157 ding assays demonstrated that these putative RAR antagonists compete directly with retinoic acid for

158 RA-RARs can activate or repress transcription of key develo

159 In cultured CD cells, RA/RAR activity was repressed by acetylcholine, albumin, al

160 Hence, RA/RAR in CD cells is a convergence point of regulation by

161 y disease (ARPKD) had significantly lower RA/RAR activity.

162 y albuminuria was associated with reduced RA/RAR activity in CD cells.

163 A-568 was more potent than RA in rescuing RA/RAR activity repressed by albumin, high glucose, angiote

164 Response-adaptive randomization (RAR) has recently gained popularity in clinical trials.

165 e assigned to 1 of 32 risk at randomization (RAR) groups created to share one-thirty-second of total

166 by comparing the ratio of annotation rates (RAR) for the same GO term across different taxonomic gro

167 BP-II directly binds to the nuclear receptor RAR to form a complex through which RA is "channeled" fr

168 e identified several retinoic acid receptor (RAR) agonists that reduced secreted ApoC-III levels in h

169 n (h) ADA3 regulates retinoic acid receptor (RAR) alpha-mediated transactivation.

170 he nuclear receptors retinoic acid receptor (RAR) and peroxisome proliferator-activated receptor (PPA

171 binding behavior of retinoic acid receptor (RAR) and retinoid X receptor (RXR) is revealed, and an e

172 The retinoic acid receptor (RAR) and retinoid X receptor (RXR) mediate the cellular

173 olved the binding of retinoic acid receptor (RAR) and retinoid X receptor (RXR) to a dominant site in

174 ion was inhibited by retinoic acid receptor (RAR) antagonists or siRNAs, but augmented by several RAR

175 l crossover onto the retinoic acid receptor (RAR) compared to all-trans-retinoic acid, with select an

176 is the ligand of the retinoic acid receptor (RAR) family of transcription factors, which interact wit

177 The retinoic acid receptor (RAR) gamma agonist CD1530 was as potent an inhibitor of

178 reviously shown that retinoic acid receptor (RAR) gamma-deficient mice have hematopoietic defects, so

179 receptors including retinoic acid receptor (RAR) have been proposed to play a protective role in pod

180 lly activated by the retinoic acid receptor (RAR) in response to its natural agonist ligand, all-tran

181 y a new role for the retinoic acid receptor (RAR) in the anterior of the embryo, where RAR regulates

182 role of each of the retinoic acid receptor (RAR) isoforms in the clonal expansion, differentiation,

183 T cells expressing a retinoic acid receptor (RAR) response element luciferase reporter responded to i

184 at CBFA2T3 represses retinoic acid receptor (RAR) target gene expression and inhibits all-trans-retin

185 to be controlled by retinoic acid receptor (RAR) transcription factors, but soft matrix prevents any

186 Activation of retinoic acid receptor (RAR) with all-trans-retinoic acid (RA) ameliorates gluco

187 hh), Wingless (Wnt), retinoic acid receptor (RAR), and bone morphogenetic protein (BMP).

188 ively activating the retinoic acid receptor (RAR), recruiting the coactivator PGC-1alpha and inducing

189 a dominant-negative retinoic acid receptor (RAR)-alpha mutant (RARdn) using an inducible Cre-Lox sys

190 Retinoic acid receptor (RAR)-beta signaling is involved in axonal and neurite re

191 tic silencing of the retinoic acid receptor (RAR)-beta The histone deacetylase inhibitor entinostat i

192 BMP2 in WT MSCs in a retinoic acid receptor (RAR)-dependent manner, suggesting that Rald is involved

193 oundly inhibited RXR/retinoic acid receptor (RAR)-mediated transcriptional activation.

194 xpress low levels of retinoic acid receptor (RAR)-related orphan receptor C (RORC) transcripts, these

195 he expression of the retinoic acid receptor (RAR)-related orphan receptor gammat (RORgammat).

196 tosol to the nuclear retinoic acid receptor (RAR).

197 imilar levels of the retinoic acid receptor (RAR).

198 y, the expression of retinoic acid receptor (RAR-beta) and retinoid X receptors (RXR-beta, -gamma) wa

199 c acid (RA), signaling through its receptor (RAR), is the trigger for hyperactivity.

200 All-trans-RA (tRA) and other RA receptor (RAR) agonists dramatically (>300-fold) induced Mct8.

201 ation of hepatocytes with RA or RA receptor (RAR) agonists increased CB(1)R mRNA and protein, the mos

202 ssion by activating the nuclear RA receptor (RAR) and its cognate intracellular lipid-binding protein

203 tes transcription by binding to RA receptor (RAR) and retinoid X receptor (RXR) heterodimers.

204 ession by direct interaction of RA receptor (RAR) with a target gene, but it can also act through non

205 y deliver retinoic acid (RA) to RA receptor (RAR), a nuclear receptor activated by this hormone, in t

206 tinoic acid (RA)-activated nuclear receptors RAR and PPARbeta/delta.

207 receptors (PR) and retinoic acid receptors (RAR) regulate CK5 expression and breast CSC activity.

208 ion factors such as retinoic acid receptors (RAR), peroxisome-proliferator-activated receptors (PPAR)

209 protein 5 (FABP5), retinoic acid receptors (RAR-alpha, -beta, -gamma), and retinoid X receptors (RXR

210 Retinoic acid (RA) activates RA receptors (RAR), resulting in RA response element (RARE)-dependent

211 RA acts through activation of RA receptors (RAR), which are members of the nuclear receptor superfam

212 The retinoic acid receptors (RARs or rars) and the thyroid hormone receptors are memb

213 Retinoic acid receptors (RARs) alpha, beta and gamma are key regulators of embryo

214 d (9cRA), activates retinoic acid receptors (RARs) and retinoid X receptors (RXRs) in vitro.

215 vely interacts with retinoic acid receptors (RARs) and rexinoid receptor (RXRs) subtypes in a ligand-

216 Retinoic acid receptors (RARs) heterodimerize with retinoid X receptors (RXRs) an

217 e role of adipocyte retinoic acid receptors (RARs) in mammary morphogenesis.

218 t activation of the retinoic acid receptors (RARs) in mouse liver and in human liver cell lines has a

219 we target specific retinoic acid receptors (RARs) to either PD duplicate (RA treatment or RARgamma a

220 interacts with the retinoic acid receptors (RARs) to modulate retinoic acid transcriptional activity

221 tion and binding of retinoic acid receptors (RARs) to the Hox1-Hox5 chromatin domains, which is follo

222 tion factors termed retinoic acid receptors (RARs), but this hormone can also activate the nuclear re

223 binding to nuclear retinoic acid receptors (RARs).

224 or of agonist-bound retinoic acid receptors (RARs).

225 iption factors, the retinoic acid receptors (RARs).

226 A), which activates retinoic acid receptors (RARs).

227 ly to activation of retinoic acid receptors (RARs).

228 within cells to both its nuclear receptors (RARs) and degrading enzymes (Cyp26s).

229 ation of the nuclear receptors RA receptors (RARs) and peroxisome proliferator-activated receptor bet

230 cription by binding to nuclear RA receptors (RARs) at RA response elements (RAREs), but it is unknown

231 RA receptors (RARs) have been thought to function through a binary rep

232 ive toxicity caused by nuclear RA receptors (RARs) limits its clinical application in treating cancer

233 ctions as a ligand for nuclear RA receptors (RARs) that regulate development of chordate animals.

234 his canonical function, RA and RA receptors (RARs), either as ligand-receptor or separately, play ext

235 Recombinant RAR-RXR binds these non-canonical spacings in vitro with

236 ily warfarin and those with an LMWH regimen (RAR: 0.9; 95% CI: 0.3 to 2.4).

237 t half-site spacing allosterically regulates RAR function.

238 ared with LMWH (16%; ratio of averaged risk [RAR]: 3.2; 95% confidence interval [CI]: 1.5 to 7.5), LM

239 of perturbations in the NFkappaB-RORgammat (RAR-related orphan receptor gammat) axis.

240 a novel homeostatic regulator of RXR and RXR/RAR that might contribute to hepatocarcinogenesis.

241 Numbers of patients sharing the same RAR group were compared between higher and lower enrolli

242 nrolling lower-risk patients shared the same RAR group with patients from countries enrolling higher-

243 agonists or siRNAs, but augmented by several RAR agonists.

244 UTX occupies the promoters of several RAR target genes and regulates their transcriptional out

245 n and restoration of epigenetically silenced RAR-beta expression.

246 To study skeletal-specific RAR function, we created conditional mouse mutants defic

247 tion of myotome subdivisions or the specific RAR subtype that is required for somite patterning.

248 in the tissues where it acts by stimulating RAR and RXR receptors, RA signaling during development i

249 Synthetic RAR agonist RA-568 was more potent than RA in rescuing R

250 ly represses HSPs through factors other than RAR, PPAR or NFkappaB despite the presence of these fact

251 We found that RAR binding throughout the genome is highly coincident w

252 Our data imply that RAR agonist enhances RAR-RXR heterodimerization, and chr

253 The data indicate that RAR-gamma agonists are potent inhibitors of heterotopic

254 ize embryos to RA treatment, indicating that RAR availability is not limiting in the embryo.

255 We show, on a genome-wide scale, that RAR alpha and ER can co-occupy regulatory regions togeth

256 We now show that RAR alpha is required for efficient estrogen receptor-al

257 We also show that RAR-beta signaling promotes the binding of the mitochond

258 Previous studies have suggested that RAR is present in the caudal domain, but is quiescent un

259 In sum, our data reveal that RARs, and RARgamma in particular, exert previously unapp

260 The RAR alpha 1 isoform was not essential for RA-dependent e

261 The RAR-related orphan receptor gamma t (RORgammat) is a nuc

262 e transcription of Fgf21 is increased by the RAR agonist RA and by overexpression of RARalpha and RAR

263 s meiotic initiation through controlling the RAR-dependent expression of Stra8.

264 ing and topology of binding elements for the RAR-RXR heterodimer.

265 Rarbeta2 is the RAR subtype whose expression is most upregulated in resp

266 inhibit the process through induction of the RAR repressors SIRT1 and Ajuba.

267 s cultured in the absence or presence of the RAR-specific ligand all trans retinoic acid (RA).

268 onfiguration, it has been suggested that the RAR provides a binding site for a corepressor (SMRT or N

269 evated cholesterol efflux in response to the RAR ligand ATRA.

270 A expression appeared to be mediated via the RAR-beta receptor subtype, as ATRA remarkably induced RA

271 l agent by increasing DRA expression via the RAR-beta/HNF-1beta-dependent pathway.

272 ses, cells that had been pretreated with the RAR-gamma agonist did not, suggesting that they had lost

273 MCF-7 cells express all three RAR isoforms, alpha, beta, and gamma, and RXRalpha.

274 nfirmed that ATRA exerts its effects through RAR-beta.

275 he inhibition of CK5+ cell expansion through RAR/PR cross talk, may explain the efficacy of retinoids

276 neuronal differentiation is mediated through RAR in the early stages and through PPARbeta/delta in th

277 g the transcriptional activity of RA through RAR, and they demonstrate that repression of this gene i

278 LBD were less conserved: Sequences of THRs, RARs and RXRs were >/=90% similar to those of the human,

279 5, thereby displacing RA and diverting it to RAR.

280 he subsequent metabolite 4-oxo-atRA, bind to RARs and potentially have biologic activity.

281 esulting in increased potency of atRA toward RAR activation.

282 Unfortunately, RAR causes many problems, including (1) bias from tempor

283 and dermal fibroblasts and is regulated via RAR/RXR-mediated pathways.

284 Conversely, when RAR-mediated repression is reduced by overexpressing a d

285 r (RAR) in the anterior of the embryo, where RAR regulates Fgf8 expression and formation of the pre-p

286 rkably induced RAR-beta mRNA levels, whereas RAR-beta knockdown substantially attenuated the ability

287 ese findings suggest a feedback loop whereby RARs activate expression of TNIP1, which then attenuates

288 are most acute in the very setting for which RAR has been proposed, namely long-duration "platform" t

289 nd MAPKAP2, as well as those associated with RAR and Wnt/beta-catenin signaling pathways.

290 t defective in its ability to cooperate with RAR but competent in interactions with HuR suppressed ca

291 ncogenic activities both by cooperating with RAR and by stabilizing antiproliferative HuR target tran

292 tein to nucleus and for its cooperation with RAR.

293 upstream domain in hepatocytes treated with RAR agonists or 2-AG was confirmed by chromatin immunopr

294 Based on treatments with RAR isoform-selective ligands, RARalpha is the major iso

295 Together, our studies suggest that zebrafish RAR function is context-dependent and that, during early

296 ectopic expression of hyperactive zebrafish RARs induces expression of a RA-responsive reporter tran

297 ic expression of dominant negative zebrafish RARs fails to induce embryonic phenotypes that are consi

298 and that, during early patterning, zebrafish RARs function primarily as transcriptional activators an

299 Ectopic expression of wild-type zebrafish RARs does not disrupt embryonic patterning and does not

300 Here, we investigate whether zebrafish RARs function as transcriptional activators or repressor